KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Share-based Compensation: 2014-2024

Historic Share-based Compensation for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to $441.6 million.

  • BeOne Medicines' Share-based Compensation rose 22.77% to $140.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.7 million, marking a year-over-year increase of 15.88%. This contributed to the annual value of $441.6 million for FY2024, which is 20.13% up from last year.
  • Per BeOne Medicines' latest filing, its Share-based Compensation stood at $441.6 million for FY2024, which was up 20.13% from $367.6 million recorded in FY2023.
  • BeOne Medicines' 5-year Share-based Compensation high stood at $441.6 million for FY2024, and its period low was $183.5 million during FY2020.
  • In the last 3 years, BeOne Medicines' Share-based Compensation had a median value of $367.6 million in 2023 and averaged $370.8 million.
  • Data for BeOne Medicines' Share-based Compensation shows a peak YoY spiked of 36.77% (in 2020) over the last 5 years.
  • Over the past 5 years, BeOne Medicines' Share-based Compensation (Yearly) stood at $183.5 million in 2020, then skyrocketed by 31.19% to $240.7 million in 2021, then rose by 25.94% to $303.2 million in 2022, then grew by 21.26% to $367.6 million in 2023, then grew by 20.13% to $441.6 million in 2024.